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The COVID-19 pandemic had an enormous impact on our health
care system, including the care for cancer patients [1,2]. These
patients are a vulnerable group due to their compromised clinical
condition and the urgency to initiate and not interrupt the treat-
ment. Shortly after the first wave of the pandemic, we reported
on its effect on radiotherapy care throughout Europe and beyond
[3–4] based on a survey carried out in conjunction with the Amer-
ican Society for Radiation Oncology (ASTRO). In addition, numer-
ous articles and editorials have been published on the effect of
the pandemic on cancer treatment and on measures for specific
disease sites or treatment modalities [5–8].
The European SocieTy for Radiotherapy and Oncology (ESTRO)
was more recently invited by the American Society for Radiation
Oncology (ASTRO) to re-survey their members using ASTRO’s
updated questionnaire, with the aim of better understanding the
impact of the pandemic on health care provision in radiation
oncology.Materials and methods
The questionnaire, slightly modified to be used by ESTRO (see
supplementary materials), was sent on February 12, 2021, to a
total of 500 ESTRO members, 474 of whomwere registered as head
of a radiation oncology (RO) department in Europe. In addition, it
was sent to 26 representatives of other departments with no regis-
tered head. Reminder were sent after 7 and 12 days and the closure
date was February 26, 2021.Results
After 14 days, 104 (nearly) completed questionnaires were
received (response rate 21%) from 28 different countries. Most
responses were from Italy (18; 17%), Belgium (14; 13%), Spain
(11; 11%), Germany (7; 7%), Switzerland (7; 7%) and Romania (6;
6%). The remaining 41 each represented less than 5% of all
responses and were from the 22 other countries.The responding departments treat a median of 1,300 new can-
cer cases per year (range: 300–7,000), with a median number of
patients under treatment of 85 per day (range 10–550). The staff-
ing levels were at a median of 10 FTE (full time equivalent) radia-
tion oncologists (range: 1–52) and 17 FTE radiation technologists
(range: 3–140). All departments were operational. About half
(51) of the centers delivered radiotherapy at more than one loca-
tion. One center closed a satellite location due to shortage of staff.
In all other centers, all locations remained open.
A decline in cancer screening for one or more groups of patients
was seen in 69% of the centers and 71% noticed that patients were
presenting with more advanced disease than before the pandemic.
Nine per cent of the departments noticed an increase in refer-
rals in 2020 compared to 2019, with a median increase of 10%
(range 2–13%). However, 38% noticed no change and 53% reported
a decrease in patient volume. The median decrease was 10% (range
2–42%). A 1–10% decrease in practice revenue over 2020 compared
to 2019 was reported by 47 centers (50%), a 11–20% decrease in 20
centers (21%) a 21–30% decrease in 8 (9%) and a more than 30%
decrease in 7 centers (7%). Twelve centers (13%) reported an
increase in practice revenue over 2020. Causes for the reduction
in volume were delays/deferrals for certain tumor sites in 38%,
reduced referral rates in 34% and shortage of staff in 3%.
In 23% of the departments, radiotherapy for some indications
was deferred. The most frequently delayed indications were:
low-risk prostate cancer (8%), non-malignant diseases (7%) and
early stage breast cancer (3%).
The following measures were in place for the staff at the time of
the second questionnaire: Routine use of masks (100%), testing of
staff with symptoms (98%), increased sterilization of the clinic
(90%), social distancing (78%), use of gloves (63%), face shields
(40%) and/or gowns (32%) for treatments and procedures, screen-
ing prior to each shift (54%) and staggered shift scheduling (26%).
Measures for patients included the routine use of masks (96%),
social distancing (92%), allowing no visitors (76%) and screening
at the front door (75%). Table 1 shows a comparison with measures
in place during the start of the pandemic.
Telemedicine was used in 65% of the departments. It was used
for new patients in 12%, clinical assessment of patients under
treatment in 11% of the departments and for routine follow-up in
64%.
Table 1






Deffered treatment 58% 23%
Telemedicine 78% 65%
Routinely using masks by personnel 88% 100%
Staggered shift scheduling 58% 26%
Social distancing 88% 78%
Patient screening for symptoms at front door 82% 75%
No visitors allowed 88% 76%
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(55%). This was due to Covid-19 illness of the patient (50/50
departments), patient caregiver quarantine protocol or illness
(18/50 departments) and/or limited hospital capacity for
brachytherapy procedures (6/50 departments). The majority of
departments (67; 73%) created specific procedures for treatment
of Covid-19 positive patients to continue treatments without
interruptions.
Vaccination of personnel has started in 54% of the centers (49).
In 67% of the centers, all staff physicians had received at least the
first vaccine dose. These numbers were 60% for nursing staff, 58%
for physicists, 57% for resident physicians, 55% for RTT’s, 52% for
dosimetrists and 46% for administrative staff. Access to the vaccine
was reported as a barrier to vaccination in 54% of the centers. Dis-
trust in and/or unwillingness of staff to receive the vaccine was a
barrier in one or more persons in 23% of the centers (21).
A permanent or transitory reduction in staff was observed in
70% of the departments. Main reasons included Covid-19 illness
of staff in 50% of the departments, impact of the COVID-19 pan-
demic on family care responsibilities in 43%, staff transfer to other
clinical areas in 16% and reduced number of patients visits in 4%.
Covid-19 illness in some or more residents was seen in 62% of
the departments, in 78% of oncologists, in 76% of radiotherapy
technologists (RTT’s) and nursing staff, in 44–49% of physicists,
dosimetrists and administrative staff.
Shortages of personal protective equipment during the pan-
demic were reported by 29% of the departments, of medical hand
sanitizer and of nasopharyngeal swabs for Covid-19 specimen col-
lection in 12% each.
Clinical and/or translational research is conducted in 68% of the
centers (65). Fifty-nine centers had open clinical trials and seven of
them (12%) noticed an increase in enrollment, whereas 58% noticed
a decrease and 31% noticed no change in the enrolled number of
patients. New Covid-19 research concepts were added to the
research portfolio in 45% of the centers.
The department heads expressed concerns related to the well-
being of health professionals (76%), creating flexible work arrange-
ments for staff with family needs (66%), burnout of health profes-
sionals (61%), and work/life balance of health professionals (54%).Discussion
Compared to the questionnaire in 2020 [3], the response to this
second questionnaire was lower (21 vs. 28%), with especially fewer
responses from The Netherlands and the United Kingdom. This is a
potential bias that complicates direct comparison. Our study did
not evaluate the introduction of more hypofractionated radiother-
apy schemes. A population-based study in the United Kingdom
recently demonstrated a decline in radiotherapy activity, but also
an increased use of hypofractionation for various indication and
potentially a shift from surgical treatments to radiotherapy [9].142During the first year of the COVID-19 pandemic radiotherapy
departments have tried to continue their care as much as possible
and to deliver timely and uninterrupted courses to all patients. A
decrease in referrals was seen in about half of the centers. This
decrease was mostly caused by their own decision to delay or defer
treatment and a reduced referral rate. Surprisingly, 10% of the cen-
ters saw some increase in patient volume.
Compared to the first questionnaire in May 2020 [3], reduction
of staff was seen more often (70 vs. 57%), mainly due to Covid-
disease and family care. Most departments acknowledge the effect
of the pandemic on the workload, work-life balance and the risk of
burnout. Protective measures for staff and patients were main-
tained during the pandemic. The use of telemedicine was some-
what reduced compared to 2020, with 65% instead of 78% of the
centers using telemedicine, and mainly used for follow-up visits.
This questionnaire was filled in around 2 months after the start
of vaccination in most countries. Just over half of the centres had
started vaccination of personnel, and depending on the discipline,
45–67% of the personnel in these departments had received their
first dose. Access to the vaccine was still an important problem
in 54% of the centers, while hesitance to take the vaccine in one
or more employees was an issue in 23% of the centers.
The pandemic also had an effect on clinical and translational
research with fewer patients entered into trials. It is also interest-
ing to see that 45% of the centers mention that they started new
research related to Covid-19.
In conclusion, radiotherapy departments throughout Europe
managed to continue the treatment of the patients. Around 70%
of the centers already reported a decline in screening and noticed
an increase in patients presenting with more advanced disease
for one or more indications. The current back-log in referred
patients will probably lead to a future increase in radiotherapy
referrals. In addition, the decrease in number of treated patients
could lead to future presentations with more advanced disease.
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